Nsclc (original) (raw)
Latest News for: nsclc
GFH375/VS-7375 Granted with FDA's Fast Track Designation for Treatment of KRAS G12D-mutant Unresectable Locally Advanced or Metastatic NSCLC (Apricot Capital)
Public Technologies 08 Jun 2026
... locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody either concurrently or sequentially.
Massive Bio & Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage NSCLC Patients
The Daily Record - Dunn 03 Jun 2026
Lung cancer risk detection meets precision trial matching, connecting high-risk patients to life-saving research at the ....
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session (Apricot Capital)
Public Technologies 01 Jun 2026
... improvement in overall survival (OS) as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC) in the Phase III HARMONi-6 (AK112-306) study.
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
PR Newswire 01 Jun 2026
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels ... Elisrasib as First-Line Monotherapy for Patients with KRAS G12C Mutation–Positive NSCLC.
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
PR Newswire 01 Jun 2026
The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future ... To know more about best ADCs in EGFR NSCLC, visit @ EGFR NSCLC Medication ... EGFR NSCLC Market Report .
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
PR Newswire 01 Jun 2026
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression ... lung cancer (NSCLC).
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in ...
The Essex Reporter 31 May 2026
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan ...
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with ...
The Essex Reporter 31 May 2026
Oral presentation of DZD6008 demonstrated strong and durable ...
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
PR Newswire 31 May 2026
One study evaluated DZD6008, an investigational fourth-generation EGFR TKI, in pre-treated NSCLC patients with EGFR C797X mutations following progression on third-generation EGFR TKI treatment.
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
PR Newswire 31 May 2026
It is also the first in sq-NSCLC to achieve dual OS and PFS success through a pre-specified hypothesis test ... It has also shown superior PFS versus pembrolizumab monotherapy in first-line PD-L1-positive NSCLC.
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
PR Newswire 31 May 2026
... treatment for patients with locally advanced or metastatic PD-L1 TPS≥1% NSCLC ... This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC.
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China (Summit Therapeutics Inc)
Public Technologies 31 May 2026
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China.
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at ...
The Daily Times 30 May 2026
CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan ...